Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan Corp. PLC

Division of Perrigo Co. PLC
www.elan.com

Latest From Elan Corp. PLC

Perrigo Faces $370m Tax Payment From Second IRS Audit Linked To Elan Deal

Even though consumer health products and Rx generics manufacturer reported $92.2m net Q3 income after losing $67.5m a year ago, investors apparently reacted more strongly to its latest tax dispute. Its share price closed down 6.7% at $50.51 on trading at twice the stock's average volume.
OTC Drugs Tax

Perrigo Pegs Growth To Initiating OTC Switches, Not Following Brands' NDAs

"A foundation of this business has been," says Perrigo's Americas consumer business chief, Jeffrey Needham, "we are a fast follower. That's been our traditional model. We can't afford to do that going forward." In addition to initiating moving ingredients from Rx to OTC, firm is developing "national better brand" versions of drugs already available OTC.

OTC Drugs Prescription To Otc Switch

Perrigo's Q1 Results Offer Scant Support To Promote Its 'Self-Care' Turnaround

President and CEO Murray Kessler attempts to temper expectations before investor day on May 9 saying Perrigo's turnaround under strategy implemented after he joined firm in November is in its early days. Private label leader, however, will report another step in its move to return to being consumer product-focused: agreement to sell its animal health business to PetIQ for $185m cash.

OTC Drugs Commercial

IRS Notice Pushes Perrigo's Potential Tax Debt From Move To Ireland Close To $3bn

IRS tax assessment for 2013, the year Perrigo acquired Dublin-based Elan, adds another cloud to OTC private label giant's outlook as it prepares to present plans for accelerating growth for its long-slumping consumer health business in the US and Europe at a March 9 investor day conference. Perrigo shares dropped more than 9% in early trading after IRS notice became known to investors before inching upward and ending at $47.92, down 6.8% from the previous day's close.

Health Advertising, Marketing & Sales
See All

Company Information

UsernamePublicRestriction

Register